DE69735856D1 - Il-12 als adjuvanz für bordetella pertussis impfstoffe - Google Patents

Il-12 als adjuvanz für bordetella pertussis impfstoffe

Info

Publication number
DE69735856D1
DE69735856D1 DE69735856T DE69735856T DE69735856D1 DE 69735856 D1 DE69735856 D1 DE 69735856D1 DE 69735856 T DE69735856 T DE 69735856T DE 69735856 T DE69735856 T DE 69735856T DE 69735856 D1 DE69735856 D1 DE 69735856D1
Authority
DE
Germany
Prior art keywords
adjuvanz
bordetella pertussis
pertussis vaccines
vaccines
bordetella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69735856T
Other languages
English (en)
Other versions
DE69735856T2 (de
Inventor
H Mills
P Mahon
S Ryan
Fiona Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Ireland Maynooth
Original Assignee
National University of Ireland Maynooth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Ireland Maynooth filed Critical National University of Ireland Maynooth
Publication of DE69735856D1 publication Critical patent/DE69735856D1/de
Application granted granted Critical
Publication of DE69735856T2 publication Critical patent/DE69735856T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • A61K2039/55527Interleukins
    • A61K2039/55538IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69735856T 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe Expired - Fee Related DE69735856T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US829865 1992-02-03
US1587196P 1996-05-31 1996-05-31
US15871P 1996-05-31
US82986597A 1997-03-31 1997-03-31
PCT/US1997/008802 WO1997045139A2 (en) 1996-05-31 1997-05-30 Il-12 as an adjuvant for bordetella pertussis vaccines

Publications (2)

Publication Number Publication Date
DE69735856D1 true DE69735856D1 (de) 2006-06-14
DE69735856T2 DE69735856T2 (de) 2006-11-16

Family

ID=26687907

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735856T Expired - Fee Related DE69735856T2 (de) 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe

Country Status (10)

Country Link
US (5) US6929794B1 (de)
EP (2) EP1015026B1 (de)
JP (2) JP3737519B2 (de)
AT (1) ATE325621T1 (de)
AU (1) AU724743B2 (de)
DE (1) DE69735856T2 (de)
DK (1) DK1015026T3 (de)
ES (1) ES2262181T3 (de)
PT (1) PT1015026E (de)
WO (1) WO1997045139A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
CN1200730C (zh) * 1998-02-12 2005-05-11 惠氏控股有限公司 用白细胞介素-12配制的肺炎球菌和脑膜炎球菌疫苗
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
EP1058557A1 (de) * 1998-03-05 2000-12-13 The Medical College Of Ohio Steigerung der immunität durch intranasale verabreichung von il-12
US6303114B1 (en) * 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GEP20053446B (en) 1999-05-13 2005-02-25 Wyeth Corp Adjuvant Combination Formulations
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
AU2001270031B2 (en) * 2000-06-22 2005-11-03 Wyeth Holdings Corporation QS-21 and IL-12 as an adjuvant combination
EP1343527A2 (de) * 2000-11-10 2003-09-17 American Cyanamid Company Adjuvante kombinationsformulierungen
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
MX347177B (es) * 2011-02-04 2017-04-17 Zoetis Services Llc Composiciones inmunogenas de bordetella bronchiseptica.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4705686A (en) * 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
JPH01193231A (ja) * 1988-01-27 1989-08-03 Takeda Chem Ind Ltd 抗腫瘍剤
DE68926859T2 (de) 1988-11-10 1997-02-13 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
WO1991001143A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Stable vaccine compositions containing interleukins
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
AU684050B2 (en) 1992-07-13 1997-12-04 Baylor College Of Medicine Targeting somatic gene therapy to joints
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
JPH10502366A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
AU3735095A (en) 1994-09-30 1996-04-26 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
JP3939752B2 (ja) * 1994-10-05 2007-07-04 バンダービルト ユニバーシティー パラミクソウイルスワクチン用アジュバントとしてのインターロイキン−12
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines

Also Published As

Publication number Publication date
US6929794B1 (en) 2005-08-16
ATE325621T1 (de) 2006-06-15
DE69735856T2 (de) 2006-11-16
WO1997045139A3 (en) 1998-02-12
US20050158276A1 (en) 2005-07-21
WO1997045139A2 (en) 1997-12-04
JP2005112865A (ja) 2005-04-28
JP3737519B2 (ja) 2006-01-18
JP2001527516A (ja) 2001-12-25
ES2262181T3 (es) 2006-11-16
US20060263380A1 (en) 2006-11-23
PT1015026E (pt) 2006-08-31
US20060257419A1 (en) 2006-11-16
EP1015026B1 (de) 2006-05-10
DK1015026T3 (da) 2006-09-11
US20060263379A1 (en) 2006-11-23
EP1015026A2 (de) 2000-07-05
EP1649868A1 (de) 2006-04-26
AU724743B2 (en) 2000-09-28
AU3567097A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
ATE325621T1 (de) Il-12 als adjuvanz für bordetella pertussis impfstoffe
EP0597852A4 (de) Impfstoff gegen die pneumonie bei schweinen und methode ihrer präparation.
ITRM940376A0 (it) Dispositivo di controllo del funzionamento di un condizionatore d'ariae metodo per questo scopo.
ATE349890T1 (de) Adjuvant für transkutane immunisation
ID21924A (id) Olanzapin dihidrat d
NL300403I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
HK1044890A1 (zh) 新的疫苗佐劑和疫苗
DE69930166D1 (de) Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
ES2133672T3 (es) Composiciones de un concentrado en suspension de agentes insecticidas y acaricidas a base de arilpirrol.
NO892997L (no) Bordetella pertussis vaksine.
ITAN940011A0 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
ES2136443T3 (es) Limpieza in situ.
FI914433A (fi) Gen som kodar ett 30 kilodaltons yttermembranprotein fraon bordetella pertussis.
ITAN940006U3 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
IT220039Z2 (it) Dispositivo di supporto ammortizato, per avvitatori e simili
IT9047612A0 (it) Dispositivo di ancoraggio di protesi dentarie e suo metodo di installazione.
IT9020880A0 (it) Dispositivo e metodo per la proiezione di diapositive.
HUP9902885A1 (hu) Maláriaellenes vakcinakészítmények

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee